Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Adefovir 10 Mg Tablets 30 By Sigma Pharma.

Adefovir 10 Mg Tablets 30 By Sigma Pharma.

Call for Price

Adefovir 10 Mg Tablets 30 By Sigma Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXA322295/RXB10125796 /RXD4914172
Size : 30
Selling UoM : EA
NDC: 42794-0003-08
UPC Barcode : 342794003080
Supplier: 0050002993 SIGMAPHARM LABORATORIES INC
Supplier Material : 000308
Generic Code : 050937 ADEFOVIR DIPIVOXIL ORAL TABLET 10 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GRX Generi

Have a question?

  Call for Price

Product Description.:

Logo and 3
tablet , white , round round
White to off-whiteLogo resembles a sigma symbolFlat-faced beveled-edg

HEPSERA
(adefovir dipivoxil) Tablets logo and 3
tablet , white , round round
White to off-whiteLogo resembles a sigma symbolFlat-faced beveled-edg

WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS, NEPHROTOXICITY, HIV RESISTANCE, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS

Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-Hepatitis B therapy including HEPSERA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-Hepatitis B therapy. If appropriate, resumption of anti-Hepatitis B therapy may be warranted [see WARNINGS AND PRECAUTIONS].

In patients at risk of or having underlying renal dysfunction, chronic administration of HEPSERA may result in nephrotoxicity. These patients should be monitored closely for renal function and may require dose adjustment [see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION].

HIV resistance may emerge in chronic hepatitis B patients with unrecognized or untreated Human Immunodeficiency Virus (HIV) infection treated with anti-hepatitis B therapies, such as therapy with HEPSERA, that may have activity against HIV [WARNINGS AND PRECAUTIONS].

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [see WARNINGS AND PRECAUTIONS].
DRUG DESCRIPTION

HEPSERA? is the tradename for adefovir dipivoxil, a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV).

Adefovir dipivoxil is a white to off-white crystalline powder with an aqueous solubility of 19 mg/mL at pH 2.0 and 0.4 mg/mL at pH 7.2. It has an octanol/aqueous phosphate buffer (pH 7) partition coefficient (log p) of 1.91.

HEPSERA tablets are for oral administration. Each tablet contains 10 mg of adefovir dipivoxil and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, pregelatinized starch, and talc.

INDICATIONS

HEPSERA is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.

For patients 12 to < 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function.


SIDE EFFECTS

The following adverse reactions are discussed in other sections of the labeling:

* Severe acute exacerbations of Hepatitis [see Boxed Warning, WARNINGS AND PRECAUTIONS]
* Nephrotoxicity [see Boxed Warning, WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with HEPSERA.

Adverse reactions to HEPSERA identified from placebo-controlled and open label studies include the following: asthenia, headache, abdominal pain, diarrhea, nausea, dyspepsia, flatulence, increased creatinine, and hypophosphatemia.